Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

CONCOR-1 Trial Description: A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness. This is a prospective randomized control trial that is comparing convalescent plasma to standard of care in adult patients admitted to Canadian hospitals with respiratory complications from COVID-19. Intervention will be 500 mL of convalescent plasma from donors with SAR-CoV-2 neutralizing antibodies in addition to standard of care. We are not yet enrolling patients. There will be between 40-60 sites participating across Canada.

Study team
Donald Arnold
Donald Arnold
MD
Hamilton Health Sciences Centre
Trial name Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19
Type of trial Phase I
Trial ID NCT04334980
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
British Columbia, Nova Scotia
Trial description

Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL. Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2. Placebo will consist of bacterial medium without bacteria.

Study team
Manish
Dr. Manish Sadarangani
Dphil
Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia.
Joanne Langley
Dr. Joanne Langley
MD
Canadian Center for Vaccinology Dalhousie University, IWK Health Centre
Trial name Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Type of trial Phase II
Trial ID NCT 04315298
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
United States, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of severity strata. (This initiative also has pan-Canadian sites.)

Study team
Trial name Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Type of trial Phase II
Trial ID NCT04321993
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Nova Scotia
Trial description

Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment. All hospitalized persons with moderate to severe COVID-19 disease that meet eligibility criteria will be offered participation.

Study team
Lisa Barrett
Dr. Lisa Barrett
MD
Dalhousie University
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Does not require Health Canada approval
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Yukon, Northwest Territories, Nunavut
Trial description

This study is an adaptive, randomized, open-label, controlled clinical trial.Subjects will be randomized to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for COVID-19. Lopinavir/ritonavir will be administered 400 mg/100 mg orally (or weight based dose adjustment for children) for a 14-day course, or until discharge from hospital, whichever occurs first

Study team
Nelson Lee
Nelson Lee
MD
University of Alberta Hospital
Allison Mah
Allison Mah
MD
Vancouver General Hospital,
Natasha Press
Natasha Press
MD
St Paul’s Hospital
Shane English
Shane English
MD
The Ottawa Hospital
Robert Fowler
Robert Fowler
MD
Sunnybrook Health Sciences Centre
Bryan Coburn
Bryan Coburn
MD
Toronto Western Hospital
Matthew Cheng
Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Alexis Turgeon
Alexis Turgeon
MD
CHU de Québec – Université LavalRecruiting
Francois Lellouche
Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université LavalRecruiting
Francois Lamontagne
Francois Lamontagne
MD, FRCPC, MSc
Université de Sherbrooke and CIUSSS de l’Estrie – CHUS